STERIS plc reported strong financial results for Q4 fiscal 2026, with revenue surpassing expectations while EPS slightly missed analyst forecasts.
Despite the EPS miss, the stock rose 1.64% in after-hours trading to $210.85, and continued to gain, reaching $215.89 later.
Revenue for the quarter reached $1.6 billion, exceeding the forecast of $1.59 billion. EPS came in at $2.83, just below the expected $2.85.
For fiscal 2026, total revenue hit $6 billion, marking 9% growth year-over-year. Adjusted net income surpassed $1 billion for the first time.
Despite macroeconomic challenges including tariffs and inflation, EBIT margins expanded by 10 basis points to 23.3%.
With a market cap of $21.21 billion and a P/E ratio of 27.05, STERIS trades at an attractive valuation. Its PEG ratio of 0.57 suggests the stock is discounted relative to its growth potential.
According to Bond.az analysis, the company appears undervalued, with a perfect Piotroski Score of 9 indicating robust financial health.
STERIS guided for FY2027 EPS of $11.23 and revenue of $6.32 billion.
